Inhibition of TBK1 has been repeatedly suggested as a theoretical option for the treatment of systemic autoimmune diseases, primarily owing to the key role of TBK1 upstream of type I IFN expression.2026, 28 Here, we describe for the first time indications of beneficial effects on immunopathological processes by the small molecule inhibitor of TBK1 amlexanox in samples from patients with SLE, pSjD and SSc. This evidence concerns the gene TBK1 and systemic sclerosis.